Ubs Asset Management Americas Inc Moon Lake Immunotherapeutics Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 42,236 shares of MLTX stock, worth $1.67 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,236
Previous 35,814
17.93%
Holding current value
$1.67 Million
Previous $1.81 Million
24.32%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding MLTX
# of Institutions
137Shares Held
58.1MCall Options Held
124KPut Options Held
96.9K-
Bvf Inc San Francisco, CA19.8MShares$782 Million39.28% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$336 Million35.64% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.34MShares$132 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$110 Million2.15% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.19MShares$86.6 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.46B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...